Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder

Aldridge, A., Kroutil, L., Cowell, A., Reeves, D., & Van Brunt, D. (2011). Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder. PharmacoEconomics, 29(7)(1170-7690), 621 - 635.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

What's in a name? A data-driven method to identify optimal psychotherapy classifications to advance treatment research on co-occurring PTSD and substance use disorders
Article

"Show Me the Energy Costs"
Article

A new approach to a legacy concern
Chapter

Finding a way to survive